Poised to bring respite across the way of diabetics, Biofem Pharmaceuticals Nigeria Limited has launched Biobetic, a new drug that could actively delay the progression and complication of diabetes.
The new drug, which has optimum potency of vitamins and minerals that effectively help in impaired glucose tolerance, diabetes management and improvement of nerve function, was unveiled during a three-day training programme organised for the marketing staff of the company at the Lagos Chamber of Commerce and Industry (LCCI) building, Alausa, Ikeja, in June.
Speaking with Pharmanews at the event, Associate Product Manager of Biofem, Dr Christopher Abhulimhen, said Biobetic is a therapeutic supplement meant to prevent the complication that comes as a result of oxidative stress, which is an imbalance between free radicals activities and antioxidant activities in the body.
“When the body is stressed, definitely the antioxidants will come and mop up whatsoever damages that come as a result of the free radicals activities; but as soon as you have a therapeutic supplement that can help with this effect, it helps and that’s what Biobetic is meant to do,” he said.
According to Abhulimhen, Biobetic contains 300mg of alpha-lipoic acid that potentially helps as adjuvant in diabetes mellitus management. He also added that the product offers various therapeutic benefits for every Nigerian, which makes it distinct from other products.
“Nigerians need the product because on the average level, every Nigerian is going through one form of stress or another,” he noted.
Speaking earlier, Managing Director and Chief Executive Officer of the company, Mr Femi Soremekun, described the training programme as an avenue to gather the staff of the company, especially those in the marketing department, in order to share with them the goals and ideals of the company.
